Form 424B5 4D Molecular Therapeutic
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- Wall St subdued as markets pause after S&P record high; data, Mideast in focus
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
Goldman Sachs Reinstates 4D Molecular Therapeutics (FDMT) at Buy, 'Platform value to inflect via 2024 catalysts'
February 7, 2024 4:53 AM EST(Updated - February 7, 2024 5:21 AM EST)
Goldman Sachs analyst Salveen Richter reinstates coverage on 4D Molecular Therapeutics (NASDAQ: FDMT) with a Buy rating and a price target of $81.00.
The analyst comments "Given positive Ph2 intravitreal gene therapy 4D-150 data in wet age-related macular degeneration (wAMD), and the planned Ph3 initiation in 1Q25, we move from Not... More
